Skip to content

Market Newsdesk

Latest Business News in Real Time

Posted on November 12, 2020 9:37 am by Newsdesk

SFL – Third Quarter 2020 Results Presentation

Please find enclosed the presentation of the preliminary third quarter results to be held November 12, 2020, in the link below.

Attachment

  • SFL – Third Quarter 2020 Results Presentation

Post navigation

Previous PostPrevious Uncommon Giving Adds Workplace Generosity for Corporate Employee Engagement
Next PostNext InvestorBrandNetwork Named as Official Media Partner for the Benzinga Global Small Cap Conference, InvestorWire to Serve as Official Newswire

Recent Articles

  • Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting June 14, 2026 10:24 am
  • Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) June 14, 2026 10:03 am
  • Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 June 14, 2026 10:03 am
  • Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting June 14, 2026 5:18 am
  • Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL June 14, 2026 3:18 am
  • Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma June 14, 2026 3:18 am
  • Babcock & Wilcox Deadline: BW Investors Have Opportunity to Lead Babcock & Wilcox Enterprises, Inc. Securities Fraud Lawsuit June 13, 2026 7:35 pm
  • Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism June 13, 2026 4:03 pm
  • Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) June 13, 2026 12:48 pm
  • Verra Mobility Corporation (VRRM) Securities Fraud Class Action Lawsuit Filed; August 4, 2026, Lead Plaintiff Deadline June 13, 2026 12:18 pm
Proudly powered by WordPress